History

The French Atomic Energy Commission (CEA) has been studying the impact of radiation on DNA for several decades. This research has resulted in a good understanding of the essential DNA repair mechanisms.
Recently, a set of innovative biomarkers was developed providing a complete functional signature for these mechanisms. This signature is now exploited as part of powerful tools for personalized cancer treatment.
Recently, a set of innovative biomarkers was developed providing a complete functional signature for these mechanisms. This signature is now exploited as part of powerful tools for personalized cancer treatment.
DNA Repair meets diagnostics
LXRepair is a CEA spin-off building on over 25 years' research into the science behind DNA repair mechanisms and in vitro diagnostics for cancer.
Awards



Team

Stéphane ALTABA
Chief Executive Officer, PhD, ESCP
Stéphane Altaba, 55 year-old, holds a PhD in biotechnology (INPL) and a degree from the École Supérieure de Commerce de Paris (ESCP-Europe). From 1994 and for more than 12 years, Stéphane Altaba held various responsibilities within the Sanofi Group: from R&D to Industrial Affairs, then Business Development. The last position he held at Sanofi was Group Director of Oncology Agreements and Licensing.
During his 9 years with Nordic Pharma, he established several strategic partnerships with other pharmaceutical companies and set up a network of subsidiaries in Europe for the marketing of the company's main products.
In 2015, he joined Genomic Vision a molecular diagnostics company where he was a member of the board and Chief Operating Officer. He successfully reorganized the company around the main markets of interest, in diagnostics, bioproduction and precision medicine, which led to a significant growth in sales.

Dr Sylvie SAUVAIGO
President, Chief Scientific Officer
Sylvie Sauvaigo founded LXRepair, a CEA’s spin-off, in 2013. She is responsible for LXRepair R&D and clinical programs.
She is graduated of the INSA school of Engineering and has a strong background in chemistry and biochemistry. She got her PhD from University of Grenoble.
Passionate about innovation and technological breakthroughs she started her carrier as Project Manager at Cis bio international where she developed innovative diagnostic assays for infectious diseases. She joined CEA where she focused on DNA damage and DNA Repair. She led a group in the Technologies for health program to develop first-of-its-kind technology for DNA Repair characterization.

Dr Thierry MAILLET
Diagnostic & Quality Management System Manager
Thierry Maillet joined LXRepair in February 2018 as Diagnostic Development and Quality Manager.
Thierry earned a PhD in Molecular Biochemistry and Biophysics from the University of Orléans.
Thierry has over 25 years of experience in the in vitro diagnostic industry.
After 18 years at Stago as Development and Manufacturing manager, he spent nearly 5 years at the French regulatory authority for health products safety as a Certified Inspector.
Thierry has over 25 years of experience in the in vitro diagnostic industry.
After 18 years at Stago as Development and Manufacturing manager, he spent nearly 5 years at the French regulatory authority for health products safety as a Certified Inspector.

Sarah LIBERT
R&D Engineer, Lab Manager Quality, Service, Production
Sarah Libert joined LXRepair in 2014 as research engineer.
She has a Master Degree in biotechnology from the University of Science of Grenoble. She currently holds the position of service and production manager and is actively involved in implementation of quality management system and R&D programs.
She has a Master Degree in biotechnology from the University of Science of Grenoble. She currently holds the position of service and production manager and is actively involved in implementation of quality management system and R&D programs.
Throughout her career, she has developed skills in cell culture, molecular biology and biochips.
Prior to join LXRepair, she spent 7 years working in a biotechnology start-up environment at Mellitech.
Prior to join LXRepair, she spent 7 years working in a biotechnology start-up environment at Mellitech.

Dr Giovanna MUGGIOLU
R&D Project Leader
Dr. Giovanna Muggiolu joined LXRepair in November 2017 as Head of Research and Development. Her research focuses on defining a DNA Repair enzymatic signature that characterizes the patient’s response to radio and chemotherapy. Her prior research focused on molecular mechanisms induced by ionizing radiation for emerging cancer therapies. She received her M.A. from the University of Turin in Medical Biotechnologies and PhD from Bordeaux University in Cellular Biology and Physiopathology.

Bertrand TREILLARD
R&D & Quality Engineer
Bertrand Treillard joined LXRepair in September 2017 as an Engineer in Research and Development and is particularly involved in the development of LXRepair diagnostic tests. He specializes in biotechnology and molecular diagnostics. Prior to joining LXRepair, Bertrand worked on the technical development of an in vitro diagnostic test at ImmunID, allowing to obtain CE marking for the test and CLIA certification for the Lab.

Xavier TATIN
PhD student
Xavier Tatin joined LXRepair in 2018 and he is currently doing a PhD in collaboration with a CEA lab. Graduated in 2017 from AgroParisTech he also holds a master’s degree in biotechnology. His doctoral work is focused on the development and the validation of a new enzymatic assay for the characterization of DNA double-strand breaks repair.
He also worked at the University of Otago in New Zealand and at Nova Southeastern University (FL, USA).
Board members

Gwenaël HAMON
Investment chief at KREAXI
Gwenaël is Investment Director at KREAXI. He started his career in 2009 within the Siparex Group, as part of the Innovation Capital in Lyon, before joining the Kreaxi’s team in December 2012. Gwenaël has developed an expertise in innovative technology companies, particularly in the field of health, biology and chemistry. Amoeba, Theranexus, KREAXI on the Board of Directors / Supervisory Board of several companies including Nosopharm, Theranexus, Diabeloop, Fabentech, Medical 360, I-TEN.
Gwenaël is a graduate engineer from the Ecole Nationale Supérieure des Arts et Métiers (Cluny, Paris), and completed his studies by the MS Engineering Finance of EM Lyon.

Celia HART
PhD, MBA Partner at Supernova Invest
Celia has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement (now Supernova Invest) in 2005 and has since carried out the investments in several companies operating mainly in life sciences. She serves (or has served) on the Boards of several companies including Algaia, Bioaxial, Diabeloop, Fermentalg, Keranova, Uromems and Theranexus.
Prior to that Celia mainly worked for Cambridge Antibody Technology one of the most successful UK biotechnology companies (now Medimmune following its acquisition by Astra Zenena) holding different managing and product development positions including Head of Lead Optimization. She was involved in the development of several therapeutic antibodies in including some in collaboration with international biotechnology or pharmaceutical partners.
Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a Ph.D. from the University of Oxford (UK) and an MBA from Grenoble Ecole de Management (France).

Sophie MANUEL
Cardiologist
Sophie Manuel is an experienced Cardiologist. She also works as an auriculo-therapist in cancerology or as an clinical and marketing expert.

FX Desforges
FX Desforges is an experienced Manager of High Technologies/Innovative start-ups companies in various markets (Health, Maritime, Instrumentation, ….) with a broad experience in various domains (Sales & Marketing of Innovative Products, Finance, Business Plan, HR, R&D, …). Recently, he was CEO of Prestodiag SAS, a diagnostic company in food safety and previously CEO of Genewave SAS which merged with Mobidiag in 2014.
François Xavier graduated from Ecole Normale Superieure in 1983 and earned a PhD from University of Limoges in 1989.
Partners










Localization
LXRepair SAS
BIOPOLIS
5, avenue du Grand Sablon
38700 La Tronche
FRANCE